IMMUNITYBIO, INC. Financing Cash Flow
IMMUNITYBIO, INC. (IBRX) reported Financing Cash Flow of $268.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-04
- IMMUNITYBIO, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $44.44M, a 74.28% decline year-over-year.
- IMMUNITYBIO, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $223.93M.
- IMMUNITYBIO, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $54.89M, a 48.66% decline year-over-year.
- IMMUNITYBIO, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $173.52M, a 1013.59% increase year-over-year.
- IMMUNITYBIO, INC. net cash provided by (used in) financing activities for fiscal 2025 was $400.24M, a 42.12% increase from fiscal 2024.
- IMMUNITYBIO, INC. net cash provided by (used in) financing activities for fiscal 2024 was $281.63M, a 49.56% decline from fiscal 2023.
- IMMUNITYBIO, INC. net cash provided by (used in) financing activities for fiscal 2023 was $558.34M, a 139.00% increase from fiscal 2022.
- IMMUNITYBIO, INC. net cash provided by (used in) financing activities for fiscal 2022 was $233.61M, a 53.78% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $44.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $268.37M 10-Q · filed 2026-08-04 | $323.26M derived: sum of 3 quarters · filed 2026-08-04 | $496.78M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $223.93M 10-Q · filed 2026-05-07 | $278.82M derived: sum of 2 quarters · filed 2026-05-07 | $452.34M derived: sum of 3 quarters · filed 2026-05-07 | $625.15M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-12-31 | $54.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $228.41M derived: sum of 2 quarters · filed 2026-02-23 | $401.22M derived: sum of 3 quarters · filed 2026-08-04 | $400.24M 10-K · filed 2026-02-23 | ||
| 2025-09-30 | $173.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $346.33M derived: sum of 2 quarters · filed 2026-08-04 | $345.35M 10-Q · filed 2025-11-05 | $452.28M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-06-30 | $172.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $171.83M 10-Q · filed 2026-08-04 | $278.76M derived: sum of 3 quarters · filed 2026-08-04 | $294.34M derived: sum of 4 quarters · filed 2026-08-04 | ||
| 2025-03-31 | -$982.00K 10-Q · filed 2026-05-07 | $105.95M derived: sum of 2 quarters · filed 2026-05-07 | $121.53M derived: sum of 3 quarters · filed 2026-05-07 | $270.42M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $106.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $122.51M derived: sum of 2 quarters · filed 2026-02-23 | $271.40M derived: sum of 3 quarters · filed 2026-02-23 | $281.63M 10-K · filed 2026-02-23 | ||
| 2024-09-30 | $15.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $164.48M derived: sum of 2 quarters · filed 2025-11-05 | $174.70M 10-Q · filed 2025-11-05 | $375.24M derived: sum of 4 quarters · filed 2026-02-23 | ||
| 2024-06-30 | $148.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $159.12M 10-Q · filed 2025-08-05 | $359.66M derived: sum of 3 quarters · filed 2026-02-23 | $597.16M derived: sum of 4 quarters · filed 2026-02-23 | ||
| 2024-03-31 | $10.22M 10-Q · filed 2025-05-12 | $210.76M derived: sum of 2 quarters · filed 2026-02-23 | $448.27M derived: sum of 3 quarters · filed 2026-02-23 | $491.68M derived: sum of 4 quarters · filed 2026-02-23 | ||
| 2023-12-31 | $200.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $438.04M derived: sum of 2 quarters · filed 2026-02-23 | $481.45M derived: sum of 3 quarters · filed 2026-02-23 | $558.34M 10-K · filed 2026-02-23 | ||
| 2023-09-30 | $237.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $280.91M derived: sum of 2 quarters · filed 2024-11-12 | $357.80M 10-Q · filed 2024-11-12 | $467.74M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-06-30 | $43.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $120.30M 10-Q · filed 2024-08-12 | $230.24M derived: sum of 3 quarters · filed 2025-03-03 | $354.23M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-03-31 | $76.89M 10-Q · filed 2024-05-09 | $186.83M derived: sum of 2 quarters · filed 2025-03-03 | $310.81M derived: sum of 3 quarters · filed 2025-03-03 | $310.80M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2022-12-31 | $109.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $233.93M derived: sum of 2 quarters · filed 2025-03-03 | $233.91M derived: sum of 3 quarters · filed 2025-03-03 | $233.61M 10-K · filed 2025-03-03 | ||
| 2022-09-30 | $123.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $123.97M derived: sum of 2 quarters · filed 2023-11-09 | $123.67M 10-Q · filed 2023-11-09 | $449.63M derived: sum of 4 quarters · filed 2024-03-19 | ||
| 2022-06-30 | -$15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$313.00K 10-Q · filed 2023-08-08 | $325.64M derived: sum of 3 quarters · filed 2024-03-19 | $368.30M derived: sum of 4 quarters · filed 2024-03-19 | ||
| 2022-03-31 | -$298.00K 10-Q · filed 2023-05-11 | $325.65M derived: sum of 2 quarters · filed 2024-03-19 | $368.31M derived: sum of 3 quarters · filed 2024-03-19 | $466.65M derived: sum of 4 quarters · filed 2024-03-19 | ||
| 2021-12-31 | $325.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $368.61M derived: sum of 2 quarters · filed 2024-03-19 | $466.95M derived: sum of 3 quarters · filed 2024-03-19 | $505.44M 10-K · filed 2024-03-19 | ||
| 2021-09-30 | $42.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $140.99M derived: sum of 2 quarters · filed 2022-11-09 | $179.49M 10-Q · filed 2022-11-09 | $179.73M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | $98.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $136.83M 10-Q · filed 2022-08-08 | $137.07M derived: sum of 3 quarters · filed 2023-03-01 | $200.29M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $38.50M 10-Q · filed 2022-05-10 | $38.74M derived: sum of 2 quarters · filed 2023-03-01 | $101.95M derived: sum of 3 quarters · filed 2023-03-01 | $189.29M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $241.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $63.46M derived: sum of 2 quarters · filed 2023-03-01 | $150.80M derived: sum of 3 quarters · filed 2023-03-01 | $150.68M 10-K · filed 2023-03-01 | $86.97M 10-K · filed 2021-03-04 | |
| 2020-09-30 | $63.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $150.56M derived: sum of 2 quarters · filed 2021-11-12 | $150.43M 10-Q · filed 2021-11-12 | $86.73M 10-Q · filed 2020-11-09 | $226.06M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $87.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $87.22M 10-Q · filed 2021-08-12 | $162.84M derived: sum of 3 quarters · filed 2022-03-01 | $162.80M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | -$123.00K 10-Q · filed 2021-05-14 | $75.50M derived: sum of 2 quarters · filed 2022-03-01 | $75.46M derived: sum of 3 quarters · filed 2022-03-01 | $74.96M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $75.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $75.58M derived: sum of 2 quarters · filed 2022-03-01 | $75.08M derived: sum of 3 quarters · filed 2022-03-01 | $114.28M 10-K · filed 2022-03-01 | $38.59M 10-K · filed 2020-03-25 | |
| 2019-09-30 | -$40.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$541.00K derived: sum of 2 quarters · filed 2020-11-09 | $38.65M 10-Q · filed 2020-11-09 | $38.28M derived: sum of 4 quarters · filed 2021-03-04 | ||
| 2019-06-30 | -$501.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $38.69M 10-Q · filed 2020-08-07 | $38.32M derived: sum of 3 quarters · filed 2021-03-04 | $38.21M derived: sum of 4 quarters · filed 2021-03-04 | ||
| 2019-03-31 | $39.20M 10-Q · filed 2020-05-11 | $38.83M derived: sum of 2 quarters · filed 2021-03-04 | $38.71M derived: sum of 3 quarters · filed 2021-03-04 | $38.51M derived: sum of 4 quarters · filed 2021-03-04 | ||
| 2018-12-31 | -$370.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$485.00K derived: sum of 2 quarters · filed 2021-03-04 | -$686.00K derived: sum of 3 quarters · filed 2021-03-04 | -$771.00K 10-K · filed 2021-03-04 | ||
| 2018-09-30 | -$115.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | -$316.00K derived: sum of 2 quarters · filed 2019-11-05 | -$401.00K 10-Q · filed 2019-11-05 | -$3.54M derived: sum of 4 quarters · filed 2020-03-25 | ||
| 2018-06-30 | -$201.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | -$286.00K 10-Q · filed 2019-08-06 | -$3.43M derived: sum of 3 quarters · filed 2020-03-25 | -$18.38M derived: sum of 4 quarters · filed 2020-03-25 | ||
| 2018-03-31 | -$85.00K 10-Q · filed 2019-05-08 | -$3.23M derived: sum of 2 quarters · filed 2020-03-25 | -$18.17M derived: sum of 3 quarters · filed 2020-03-25 | |||
| 2017-12-31 | -$3.14M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | -$18.09M derived: sum of 2 quarters · filed 2020-03-25 | -$34.98M 10-K · filed 2020-03-25 | |||
| 2017-09-30 | -$14.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$31.84M 10-Q · filed 2018-11-07 | ||||
| 2017-06-30 | -$16.89M 10-Q · filed 2018-08-06 | |||||
| 2016-12-31 | -$15.56M 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |